CRMD vs DBVT vs HALO vs ALKS

For growth investors, CorMedix Inc.

(CRMD) is the stronger pick with 617. 0% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). CorMedix Inc. (CRMD) offers the better valuation at 3. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate CorMedix Inc. (CRMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, CorMedix Inc.

(CRMD) is the cheapest at 3. 9x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HALO returned +559. 7% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus CorMedix Inc. 's 1. 42β — meaning CRMD is approximately 178% more volatile than HALO relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 37% for CorMedix Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CorMedix Inc.

(CRMD) is pulling ahead at 617. 0% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: CorMedix Inc. grew EPS 780. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, CRMD leads at 1583% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CorMedix Inc.

(CRMD) is the more profitable company, earning 52. 3% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 52. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — CRMD leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 0x forward P/E versus 14. 2x for CorMedix Inc. — 6. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Both have compounded well over 10 years (HALO: +559. 7%, CRMD: -51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CRMD is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; ALKS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.